Recombinant vaccines for hepatitis E.
Hepatitis E virus causes epidemics of acute hepatitis in many developing countries. It infrequently causes disease in developed countries, but avirulent strains might circulate. Some evidence suggests that hepatitis E might be a zoonosis. There is probably only a single serotype. A candidate vaccine consisting of baculovirus-expressed recombinant capsid protein protected macaques from hepatitis E--it passed phase I clinical trials and is currently scheduled for phase II/III clinical trials.
Emerson
S U
SU
Molecular Hepatitis and Hepatitis Viruses Sections, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. semerson@niaid.nih.gov
Purcell
R H
RH
D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D016751:Hepatitis E / Q000276:immunology* / Q000517:prevention & control*; D016752:Hepatitis E virus / Q000235:genetics / Q000276:immunology / Q000502:physiology; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods / Q000639:trends; D011994:Recombinant Proteins / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology*; D014761:Viral Hepatitis Vaccines / Q000235:genetics / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology
C400971:ORF2 protein, Hepatitis E virus; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines; D014764:Viral Proteins